Biotech · Private company · Hayward, CA, US
Planet Biotechnology, Inc.
Track this companyFree. Adds Planet Biotechnology, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards9
- Developing a Potent Broad-Spectrum Prophylactic for Tickborne DiseaseFiscal year 2025 · $300KNIH RePORTER 5R41AI179571-02 · fetched Nov 12, 2026
- A broad spectrum anti-gonorrhea immunotherapeuticFiscal year 2025 · $296.9KNIH RePORTER 5R41AI179576-02 · fetched Nov 12, 2026
- Factor H-Fc Fusion as a Pre-Exposure Prophylactic for Rickettsia InfectionsFiscal year 2025 · $295.4KNIH RePORTER 5R43AI186978-02 · fetched Nov 12, 2026
- Bispecific antibody for topical administration to prevent gonorrheaFiscal year 2025 · $300KNIH RePORTER 5R43AI186979-02 · fetched Nov 12, 2026
- Developing a Potent Broad-Spectrum Prophylactic for Tickborne DiseaseFiscal year 2024 · $300KNIH RePORTER 1R41AI179571-01A1 · fetched Nov 12, 2026
- A broad spectrum anti-gonorrhea immunotherapeuticFiscal year 2024 · $300KNIH RePORTER 1R41AI179576-01A1 · fetched Nov 12, 2026
- Factor H-Fc Fusion as a Pre-Exposure Prophylactic for Rickettsia InfectionsFiscal year 2024 · $300KNIH RePORTER 1R43AI186978-01 · fetched Nov 12, 2026
- Bispecific antibody for topical administration to prevent gonorrheaFiscal year 2024 · $300KNIH RePORTER 1R43AI186979-01 · fetched Nov 12, 2026
- Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infectionsFiscal year 2024 · $300KNIH RePORTER 5R41AI177227-02 · fetched Nov 12, 2026